[go: up one dir, main page]

MX2011011156A - COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2. - Google Patents

COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.

Info

Publication number
MX2011011156A
MX2011011156A MX2011011156A MX2011011156A MX2011011156A MX 2011011156 A MX2011011156 A MX 2011011156A MX 2011011156 A MX2011011156 A MX 2011011156A MX 2011011156 A MX2011011156 A MX 2011011156A MX 2011011156 A MX2011011156 A MX 2011011156A
Authority
MX
Mexico
Prior art keywords
compounds
agonist activity
receptor antagonist
receptor agonist
diamide compounds
Prior art date
Application number
MX2011011156A
Other languages
English (en)
Inventor
John R Jacobsen
Yan Chen
Adam Hughes
Eric L Stangeland
Daniel Byun
Melissa Fleury
Richard D Wilson
Rose Yen
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MX2011011156A publication Critical patent/MX2011011156A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se refiere a un compuesto de fórmula I: (ver fórmula (I)) o una sal farmacéuticamente aceptable del mismo. Dichos compuestos poseen actividad tanto como antagonistas de los receptores muscarínicos cuanto como agonistas de los receptores adrenérgicos ß2. La invención también se refiere a composiciones farmacéuticas que comprenden dichos compuestos, procesos e intermediarios para preparar dichos compuestos, y métodos para usar dichos compuestos como agentes broncodilatadores para tratar trastornos pulmonares.
MX2011011156A 2009-04-23 2010-04-16 COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2. MX2011011156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17203909P 2009-04-23 2009-04-23
PCT/US2010/031356 WO2010123766A1 (en) 2009-04-23 2010-04-16 DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publications (1)

Publication Number Publication Date
MX2011011156A true MX2011011156A (es) 2011-11-04

Family

ID=42272140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011156A MX2011011156A (es) 2009-04-23 2010-04-16 COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.

Country Status (31)

Country Link
US (14) US8138345B2 (es)
EP (3) EP3210981B1 (es)
JP (3) JP5671006B2 (es)
KR (1) KR101769061B1 (es)
CN (2) CN102405218B (es)
AR (1) AR076412A1 (es)
AU (1) AU2010239522B2 (es)
BR (1) BRPI1014877B8 (es)
CA (1) CA2758505C (es)
CL (1) CL2011002637A1 (es)
CO (1) CO6440584A2 (es)
CY (2) CY1119008T1 (es)
DK (3) DK3210981T3 (es)
ES (3) ES2635358T3 (es)
HR (3) HRP20130468T1 (es)
HU (2) HUE042975T2 (es)
IL (1) IL215554A (es)
LT (2) LT2599778T (es)
MX (1) MX2011011156A (es)
MY (1) MY158339A (es)
NZ (1) NZ595850A (es)
PL (3) PL2599778T3 (es)
PT (3) PT2599778T (es)
RU (2) RU2543716C2 (es)
SG (1) SG175330A1 (es)
SI (3) SI3210981T1 (es)
SM (3) SMT201900168T1 (es)
TR (1) TR201903556T4 (es)
TW (2) TWI513693B (es)
WO (1) WO2010123766A1 (es)
ZA (1) ZA201107743B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2599778T3 (pl) 2009-04-23 2018-01-31 Theravance Respiratory Co Llc Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
WO2012168349A1 (en) 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN103562198B (zh) 2011-06-10 2016-08-24 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
SG11201504318UA (en) 2012-12-06 2015-07-30 Chiesi Farma Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN105142673B8 (zh) 2012-12-18 2018-02-16 阿尔米雷尔有限公司 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
WO2016180348A1 (zh) * 2015-05-14 2016-11-17 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
TW201704211A (zh) * 2015-05-14 2017-02-01 Sichuan Haisco Pharmaceutical Co Ltd 具有β２受體激動及Ｍ受體拮抗活性的聯苯衍生物及其在醫藥上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2017125060A1 (zh) * 2016-01-22 2017-07-27 四川海思科制药有限公司 一种氮杂环酰胺衍生物及其制备方法和在医药上的用途
WO2018011090A1 (en) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ES2836113T3 (es) 2016-12-14 2021-06-24 Beijing Showby Pharmaceutical Co Ltd Clase de compuestos bifuncionales con estructura de sal de amonio cuaternario
EP3625232B1 (en) 2017-05-19 2021-06-23 Council of Scientific and Industrial Research Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
EP1235802B1 (en) 1999-12-07 2005-07-13 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
KR100889426B1 (ko) 2000-08-05 2009-03-23 글락소 그룹 리미티드 항염증제로서의 6.알파.,9.알파.-디플루오로-17.알파.-'(2-푸라닐카르복실)옥시-11.베타.-히드록시-16.알파.-메틸-3-옥소-안드로스트-1,4-디엔-17-카르보티오산 ｓ-플루오로메틸 에스테르
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US7151671B2 (en) * 2001-12-04 2006-12-19 Tokyo R & D Co., Ltd. Power supply
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN101239969B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
GEP20084452B (en) 2004-01-22 2008-08-10 Pfizer Sulfonamide derivatives for the treatment of diseases
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7307076B2 (en) 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
PL2007214T5 (pl) 2006-02-08 2014-11-28 Fuji Oil Europe Produkty jadalne o niskiej zawartości nasyconych i trans nienasyconych tłuszczów
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
DK2324018T3 (da) 2008-07-25 2013-10-14 Boehringer Ingelheim Int Cykliske inhibitorer af 11 beta-hydroxysteroid dehydrogenase 1
PL2599778T3 (pl) 2009-04-23 2018-01-31 Theravance Respiratory Co Llc Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2

Also Published As

Publication number Publication date
HUE042975T2 (hu) 2019-07-29
MY158339A (en) 2016-09-30
ES2635358T3 (es) 2017-10-03
PL2421849T3 (pl) 2013-08-30
US8138345B2 (en) 2012-03-20
US20170362200A1 (en) 2017-12-21
US8551978B2 (en) 2013-10-08
HRP20130468T1 (en) 2013-06-30
US8816088B2 (en) 2014-08-26
US9572802B2 (en) 2017-02-21
CL2011002637A1 (es) 2012-04-27
TW201546057A (zh) 2015-12-16
BRPI1014877A8 (pt) 2018-03-13
US9975875B2 (en) 2018-05-22
US20170226082A1 (en) 2017-08-10
EP2599778B1 (en) 2017-04-12
TWI570115B (zh) 2017-02-11
TR201903556T4 (tr) 2019-04-22
CN102405218A (zh) 2012-04-04
AU2010239522B2 (en) 2015-07-02
AR076412A1 (es) 2011-06-08
TWI513693B (zh) 2015-12-21
SI2421849T1 (sl) 2013-07-31
US20160361304A1 (en) 2016-12-15
EP3210981B1 (en) 2019-01-02
BRPI1014877B8 (pt) 2021-05-25
HRP20170960T1 (hr) 2017-09-22
JP2015147807A (ja) 2015-08-20
PL3210981T3 (pl) 2019-06-28
IL215554A0 (en) 2011-12-29
RU2011147374A (ru) 2013-05-27
CN102405218B (zh) 2014-06-04
US20130331364A1 (en) 2013-12-12
US20130137665A1 (en) 2013-05-30
EP2421849B1 (en) 2013-04-03
ZA201107743B (en) 2012-06-27
US20150274697A1 (en) 2015-10-01
CA2758505C (en) 2017-03-07
EP3210981A1 (en) 2017-08-30
RU2543716C2 (ru) 2015-03-10
DK2421849T3 (da) 2013-07-01
CO6440584A2 (es) 2012-05-15
EP2421849A1 (en) 2012-02-29
HK1165799A1 (en) 2012-10-12
US20190047984A1 (en) 2019-02-14
PL2599778T3 (pl) 2018-01-31
SI3210981T1 (sl) 2019-05-31
CY1121601T1 (el) 2020-05-29
ES2417339T3 (es) 2013-08-07
JP2012524783A (ja) 2012-10-18
US9394275B2 (en) 2016-07-19
PT3210981T (pt) 2019-04-01
US9000173B2 (en) 2015-04-07
US9771350B2 (en) 2017-09-26
CN103936716A (zh) 2014-07-23
TW201041866A (en) 2010-12-01
RU2015101032A (ru) 2015-06-27
EP2599778A1 (en) 2013-06-05
SG175330A1 (en) 2011-11-28
JP2014210816A (ja) 2014-11-13
CA2758505A1 (en) 2010-10-28
RU2676686C2 (ru) 2019-01-10
KR20110138292A (ko) 2011-12-26
US20140323733A1 (en) 2014-10-30
IL215554A (en) 2014-08-31
US9682957B2 (en) 2017-06-20
US20210024493A1 (en) 2021-01-28
WO2010123766A1 (en) 2010-10-28
RU2015101032A3 (es) 2018-07-30
US10836744B2 (en) 2020-11-17
HRP20190417T1 (hr) 2019-04-19
US20200165223A1 (en) 2020-05-28
CY1119008T1 (el) 2018-01-10
JP5671006B2 (ja) 2015-02-18
US10138220B1 (en) 2018-11-27
LT2599778T (lt) 2017-08-25
AU2010239522A1 (en) 2011-11-10
SMT201300060B (it) 2013-07-09
US20190300504A1 (en) 2019-10-03
BRPI1014877B1 (pt) 2020-11-10
BRPI1014877A2 (pt) 2016-04-12
SMT201900168T1 (it) 2019-05-10
JP5965440B2 (ja) 2016-08-03
KR101769061B1 (ko) 2017-08-17
US20100273755A1 (en) 2010-10-28
SI2599778T1 (sl) 2017-08-31
US10590107B2 (en) 2020-03-17
DK3210981T3 (en) 2019-04-01
NZ595850A (en) 2013-05-31
ES2715965T3 (es) 2019-06-07
PT2421849E (pt) 2013-05-27
PT2599778T (pt) 2017-06-06
US20170096412A1 (en) 2017-04-06
LT3210981T (lt) 2019-04-10
SMT201700305T1 (it) 2017-09-07
DK2599778T3 (en) 2017-06-26
US10358433B2 (en) 2019-07-23
HUE035049T2 (en) 2018-05-02
CN103936716B (zh) 2016-09-07

Similar Documents

Publication Publication Date Title
MX2011011156A (es) COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
MY155212A (en) Quaternary ammonium salt compounds
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
PH12013501341A1 (en) Morphinan compounds
WO2010011821A3 (en) Dual-acting antihypertensive agents
MY172806A (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
TW200800981A (en) 8-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonists
HK1197240A1 (en) New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MY171899A (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
WO2007127196A3 (en) DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
TW200716607A (en) Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists
PL1861360T3 (pl) Pochodne pirolidyny jako antagoniści receptora histaminowego H3
MX2011013149A (es) Acido (s)-2-bencil-3-((3r,4r)-4 - (3 - carbamoilfenil) -3,4-dimetilpiperidinil) propanoico y sales delmismo como antagonistas de receptores opioides.

Legal Events

Date Code Title Description
FG Grant or registration